Literature DB >> 2174762

In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.

T Fujimoto1, S Mitsuhashi.   

Abstract

DR-3355, the S-(-)-isomer of ofloxacin, possessed generally twice higher activity than ofloxacin, and its action was bactericidal. The difference in antibacterial activity of these compounds was attributable to their inhibitory activity against DNA gyrase. DR-3355 was characterized by its higher potency against gram-positive cocci and obligate anaerobes than ofloxacin and ciprofloxacin. DR-3355 was somewhat less potent than ciprofloxacin against Enterobacteriaceae and Pseudomonas aeruginosa, but was active against organisms resistant to cefteram, ceftazidime, and amikacin. The activity of DR-3355 was decreased by gyrA mutation, like that of the other quinolones, although it did not alter significantly by deficiency of outer membrane protein F or lipopolysaccharide. Moderately norfloxacin-resistant isolates of Staphylococcus aureus remained susceptible to DR-3355, but not to ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174762     DOI: 10.1159/000238777

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  21 in total

1.  Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Authors:  S C Chien; A T Chow; M C Rogge; R R Williams; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.

Authors:  N Masuda; Y Takahashi; M Otsuki; E Ibuki; H Miyoshi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.

Authors:  T M File; J Segreti; L Dunbar; R Player; R Kohler; R R Williams; C Kojak; A Rubin
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

Authors:  N Dholakia; K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Characterization and its potential application of two esterases derived from the arctic sediment metagenome.

Authors:  Jeong Ho Jeon; Jun-Tae Kim; Sung Gyun Kang; Jung-Hyun Lee; Sang-Jin Kim
Journal:  Mar Biotechnol (NY)       Date:  2008-09-24       Impact factor: 3.619

8.  In vitro activity of T-3761, a new fluoroquinolone.

Authors:  T Muratani; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Activity of levofloxacin in a murine model of tuberculosis.

Authors:  S P Klemens; C A Sharpe; M C Rogge; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Enantioselective disposition of ofloxacin in humans.

Authors:  O Okazaki; C Kojima; H Hakusui; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.